BioCryst Pharmaceuticals (BCRX) Scheduled to Post Quarterly Earnings on Monday

BioCryst Pharmaceuticals (NASDAQ:BCRX) is set to issue its quarterly earnings data before the market opens on Monday, February 26th. Analysts expect the company to announce earnings of ($0.15) per share for the quarter.

BioCryst Pharmaceuticals (BCRX) opened at $4.96 on Monday. The stock has a market cap of $488.09, a P/E ratio of -7.75 and a beta of 2.80. BioCryst Pharmaceuticals has a fifty-two week low of $3.95 and a fifty-two week high of $9.25. The company has a quick ratio of 2.53, a current ratio of 2.53 and a debt-to-equity ratio of 0.21.

BCRX has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a report on Wednesday, November 8th. Barclays began coverage on shares of BioCryst Pharmaceuticals in a research report on Wednesday, December 20th. They set an “equal weight” rating and a $6.00 target price for the company. Royal Bank of Canada raised shares of BioCryst Pharmaceuticals from a “sector perform” rating to an “outperform” rating and set a $6.00 target price for the company in a research report on Tuesday, January 2nd. BidaskClub raised shares of BioCryst Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Thursday, February 8th. Finally, ValuEngine downgraded shares of BioCryst Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research report on Wednesday, February 14th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the company’s stock. BioCryst Pharmaceuticals presently has an average rating of “Hold” and an average price target of $8.29.

ILLEGAL ACTIVITY NOTICE: This piece of content was posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The correct version of this piece of content can be viewed at

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc is a biotechnology company. The Company designs, optimizes and develops small molecule drugs that block enzymes involved in the pathogenesis of diseases. The Company focuses on the treatment of rare diseases. It uses X-ray crystallography, computer modeling of molecular structures and chemistry techniques to focus on the three-dimensional molecular structure and active site characteristics of the enzymes that control cellular biology.

Earnings History for BioCryst Pharmaceuticals (NASDAQ:BCRX)

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit